v3.26.1
Intangible Assets
 9 Months Ended 12 Months Ended
Mar. 31, 2026
Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible Assets

 

4.Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.

 

The following is a summary of the Company’s intangible assets:

 

        
   March 31, 2026   June 30, 2025 
         
Intellectual Property  $2,293,770   $2,293,770 
Less: Accumulated Amortization   (2,287,462)   (2,115,429)
Intellectual Property, net  $6,308   $178,341 

 

Amortization expense was $57,344 in each of the three-month periods ended March 31, 2026 and 2025. Amortization expense was $172,033 in each of the nine-month periods ended March 31, 2026 and 2025. The Company amortizes intellectual property over the expected original useful lives of 10 years and the remaining amortization expense for the year ending June 30, 2026 is $6,308. 

4. Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of June 30, 2025 and 2024: 

 

          
   June 30, 2025   June 30, 2024 
         
Intellectual Property  $2,293,770   $2,293,770 
Less: Accumulated Amortization   (2,115,429)   (1,886,052)
Intellectual Property, net  $178,341   $407,718 

 

Amortization expense amounted to $229,377 for each of the years ended June 30, 2025 and 2024, respectively. The Company amortized intellectual property over the expected original useful lives of 10 years and the remaining amortization expense for the year ending June 30, 2026 is $178,341.